

Amendments to the Claims

The listing of claims below is intended to replace all prior listings of claims presented in the above-identified application.

1. (Currently Amended) A method of preventing or treating Alzheimer's Disease in a subject comprising:

administering to the subject an agent which inhibits interaction between amyloid- β peptide and ~~proteins which chaperone amyloid- β~~ apolipoprotein E, compared to when the agent is absent, ~~under conditions effective~~ to prevent or treat Alzheimer's Disease in the subject.

2-3 (Canceled)

4. (Currently Amended) The method according to claim ~~3~~ 1, wherein the agent is a protein or a peptidomimetic.

5. (Original) The method according to claim 4, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4.

6. (Currently Amended) The method according to claim 1, wherein the agent has a three dimensional structure ~~like that~~ corresponding to the three dimensional structure of a protein ~~comprising~~ having an amino acid sequence of SEQ ID NOs: 3 or 4.

7. (Original) The method according to claim 1, wherein the agent is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of SEQ ID NOs: 3 or 4.

8. (Original) The method according to claim 1, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.

9. (Original) The method according to claim 1, wherein said administering is carried out orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally.

10. (Original) The method according to claim 1, wherein Alzheimer's Disease is prevented.

11. (Original) The method according to claim 1, wherein Alzheimer's Disease is treated.

12. (Currently Amended) A method of inhibiting accumulation of amyloid- β peptide deposits in a subject's brain comprising:

administering to the subject an agent which inhibits interaction between amyloid- β peptide and ~~proteins which chaperone amyloid- β~~ apolipoprotein E, compared to when the agent is absent, ~~under conditions effective~~ to inhibit accumulation of amyloid- β peptide deposits in the subject's brain.

13-14 (Canceled)

15. (Original) The method according to claim 12, wherein the agent is a protein or a peptidomimetic.

16. (Original) The method according to claim 15, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 2 or 3.

17. (Currently Amended) The method according to claim 12, wherein the agent has a three dimensional structure ~~like that~~ corresponding to the three dimensional structure of a protein ~~comprising~~ having an amino acid sequence of SEQ ID NOs: 2 or 3.

18. (Original) The method according to claim 12, wherein the agent is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of SEQ ID NOs: 3 or 4.

19. (Original) The method according to claim 12, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.

20. (Original) The method according to claim 12, wherein said administering is carried out orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally.

21. (Withdrawn) A method of inhibiting interaction between apolipoprotein E and amyloid- β comprising:
administering an agent which blocks interaction of apolipoprotein E and amyloid- β under conditions effect to block such interaction.

22. (Withdrawn) The method according to claim 21, wherein the agent is a protein or a peptidomimetic.

23. (Withdrawn) The method according to claim 21, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4.

24. (Withdrawn) The method according to claim 21, wherein the agent has a three dimensional structure like that of a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4.

25. (Withdrawn) The method according to claim 21, wherein the agent is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of SEQ ID NOs: 3 or 4.

26. (Withdrawn) The method according to claim 21, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.